Welcome to our dedicated page for Agilon Health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The agilon health, inc. (AGL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. agilon health describes itself as a trusted partner empowering physicians to transition senior patients to a value-based Total Care Model, and its filings offer detail on how this business is structured and governed.
Investors can review current and historical reports such as Form 8-K filings, where agilon health has reported items including quarterly financial results, leadership transitions, amendments to by-laws, and notices related to New York Stock Exchange continued listing standards. These documents give additional context to the company’s announcements about its operations, value-based care arrangements, and corporate governance.
Through its periodic reports referenced in these filings, agilon health discusses topics such as risk factors associated with its value-based care model, relationships with payors and physician partners, and its reliance on medical services as a source of revenue. The filings may also describe compensation and employment arrangements for key executives, as reflected in agreements disclosed in Form 8-K exhibits.
On Stock Titan, users can combine direct access to agilon health’s SEC documents with AI-powered tools that summarize key points and highlight important sections. This can help readers more quickly understand complex disclosures related to financial performance, listing status, executive arrangements, and other matters that affect agilon health’s value-based healthcare business.
agilon health, inc. appointed Tim O’Rourke as Chief Executive Officer, President and a Class III director, with his employment expected to begin on May 7, 2026. He succeeds Executive Chairman Ronald A. Williams, who will remain Chairman of the Board.
O’Rourke brings more than 25 years of healthcare experience, including senior roles at Help at Home, Humana, Centene and Ascension Complete. Under his Employment Agreement, he will receive a base salary of $850,000, target annual bonus equal to 100% of salary, and a $500,000 signing bonus subject to repayment if he departs under certain circumstances within one year.
He will be granted 120,000 time-vesting RSUs over three years and 200,000 PSUs that vest in three tranches if the Company’s stock achieves 30-day weighted average prices of $50, $100 and $150 during a three-year performance period, subject to continued employment. If terminated without cause or he resigns for good reason, he may receive 18 months of salary, a target bonus amount, extended medical coverage and partial acceleration of equity, with enhanced terms following a change in control.
agilon health, inc. will hold a virtual 2026 Annual Meeting on June 2, 2026, where stockholders will vote on electing three Class II directors, ratifying Ernst & Young as auditor, and approving executive pay on an advisory basis. The Board recommends voting FOR all three proposals. The company highlights its Total Care Model for Medicare seniors, noting about 75% of patients are in 4+ STAR Medicare Advantage plans and an average 4.2 Stars for 2026 ratings. For 2025, agilon reported $5.93 billion in revenue, a medical margin loss of $56.6 million, and a Reported Adjusted EBITDA loss of $296.2 million, and describes transformation initiatives and leadership changes, including an Executive Chairman structure and interim co-principal executive officers.
agilon health, inc. Chief Legal Officer Denise Zamore reported routine share dispositions related to taxes, not open-market sales. On two dates, a total of 240 shares of common stock were withheld by the company to cover income tax obligations from restricted stock unit net settlements.
After these tax-withholding transactions, Zamore directly holds 66,597 shares of agilon health common stock. The footnotes clarify that these entries reflect shares withheld by the issuer to satisfy tax and remittance obligations and “do not represent a sale.”
agilon health, inc. Chief Technology Officer Venkatachaliah Girish reported two small tax-related share dispositions through share withholding, not open-market sales. On April 15, 330 shares of Common Stock were withheld at $26.88 per share, and on April 14, 96 shares were withheld at $22.68 per share.
According to the footnotes, these shares were withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and do not represent sales. After these transactions, Girish directly holds 38,236 shares of Common Stock, and this amount includes restricted stock units.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported two Form 4 transactions in Common Stock. On April 15, 2026, 122 shares were withheld at $26.88 per share, and on April 14, 2026, 25 shares were withheld at $22.68 per share to satisfy tax obligations from restricted stock unit settlements. These transactions did not involve open-market sales, and Gertsch held 14,177 shares of Common Stock directly after the most recent transaction.
agilon health, inc. Chief Markets Officer Benjamin Shaker reported two small share dispositions that were solely for tax withholding. On April 15, 2026, 571 shares of Common Stock were withheld at $26.88 per share, leaving 122,850 shares held directly. On April 14, 2026, 104 shares were withheld at $22.68 per share, after which he held 123,421 shares. A footnote explains these were shares withheld by the issuer to satisfy income tax obligations in connection with net settlement of restricted stock units and do not represent open-market sales.
agilon health, inc. reported that its Chief Financial Officer, Jeffrey A. Schwaneke, received a grant of 75,000 shares of Common Stock in the form of restricted stock units on April 1, 2026. These restricted stock units vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
On the same date, 1,662 shares of Common Stock were withheld by the company to cover income tax obligations related to the net settlement of restricted stock units, and this did not represent an open-market sale. After these transactions, Schwaneke directly beneficially owned 140,342 shares, which include restricted stock units, and indirectly beneficially owned 892 shares held by a trust. The reported beneficial ownership amounts reflect a 1-for-25 reverse stock split of agilon health’s common stock that became effective on March 30, 2026.
agilon health, inc. reported that Chief Markets Officer Benjamin Shaker received a grant of 70,000 shares of Common Stock in the form of restricted stock units at $0.00 per share. On the same date, 1,664 shares were withheld at $9.75 per share to cover income tax obligations, and this did not represent an open-market sale.
After these transactions, Shaker beneficially owned 123,525 shares of Common Stock, which includes restricted stock units and reflects a 1-for-25 reverse stock split effective March 30, 2026. The restricted stock units vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported equity compensation and related tax withholding in Common Stock. He received 10,000 restricted stock units that vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
On the same date, 266 shares of Common Stock were withheld by the company to cover income tax obligations tied to the RSU net settlement; this was a tax-withholding disposition and not an open-market sale. Following these transactions, Gertsch beneficially owned 14,324 shares, a figure that reflects the issuer’s 1-for-25 reverse stock split effective March 30, 2026 and includes RSUs.